ReviewInternational journal of physiology, pathophysiology and pharmacology2019
Mechanism and adverse effects of multiple sclerosis drugs: a review article. Part 2.
Review in International journal of physiology, pathophysiology and pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Advanced Oxidative Protein Products Role in Multiple Sclerosis: a Systematic Review and Meta-analysis.Molecular neurobiology · 2021Pooled it
- Impact of aerobic exercise on clinical and magnetic resonance imaging biomarkers in persons with multiple sclerosis: An exploratory randomized controlled trial.Journal of rehabilitation medicine · 2021Trial
- Review
- Anti-Inflammatory Properties of Curcumin as Add-On Therapy in Patients with MS-Prospective, Comparative, Randomized, Pilot Study.Pharmaceutics · 2026Article
- Unusual Sequential Development of Multiple Sclerosis, Thymoma, Myasthenia, and Lymphoma in the Same Patient.Case reports in medicine · 2026Article
- Overexpression of ITGB3 in Peripheral Blood Mononuclear Cells of Relapsing-Remitting Multiple Sclerosis Patients.International journal of molecular sciences · 2025Article
- A review of multiple sclerosis: From pathophysiology to latest therapeutic advances.AIMS neuroscience · 2025Review
- Nano-based approaches for the treatment of neuro-immunological disorders: a special emphasis on multiple sclerosis.Discover nano · 2024Review
- Effect of Silybum Marianum on Reduction of Chemotherapy-Induced Peripheral Neurotoxicity with Cisplatin.Advanced biomedical research · 2024Article
- Nanoparticle-based Gene Therapy for Neurodegenerative Disorders.Mini reviews in medicinal chemistry · 2024Review
- Multiple Sclerosis-A Demyelinating Disorder and Its Dental Considerations-A Literature Review with Own Case Report.Brain sciences · 2023Review
- Evaluation of the Relative Frequency of Epstein-Barr Virus Infection in Patients with Recurrent Breast Cancer Compared with Patients with Nonrecurrent Breast Cancer.Advanced biomedical research · 2023Article
- Rituximab and Pyoderma Gangrenosum: An Investigation of Disproportionality Using a Systems Biology-Informed Approach in the FAERS Database.Drugs - real world outcomes · 2022Article
- RETRACTED: Oral Administration of Myelin Oligodendrocyte Glycoprotein Attenuates Experimental Autoimmune Encephalomyelitis through Induction of Th2/Treg Cells and Suppression of Th1/Th17 Immune Responses.Current issues in molecular biology · 2022Article
- Review
- Platelet-rich plasma therapy or arthroscopic surgery on repair of anterior cruciate ligament rupture.European journal of translational myology · 2022Article
- Review
- Evaluation of patterns, cause and risk factors of burns in patients with seizure.International journal of burns and trauma · 2022Article
- Evaluation of the serum level of osteoprotegerin and bone mineral density in postmenopausal women.International journal of physiology, pathophysiology and pharmacology · 2022Article
- Contrast-enhanced weighted-T1 and FLAIR sequences in MRI of meningeal lesions.American journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple Sclerosis (MS) is an autoimmune, inflammatory disease of the central nervous system (CNS) mostly affecting young adults. The exact mechanism and pathogenesis of MS remain still undiscovered but there have been useful treatments with different efficacy rates. Most of these therapies are divided into the first line, second line and third line, impact on the immune system and immune cells. These drugs are approved to be useful in MS, but like any other therapies, adverse effects (AE) are associated with these drugs. In this review, we continue the survey over mechanisms of actions and AEs of MS drugs. Physicians must be aware of such AEs and complications to choose the best drug for each patient.
Indexed as
Identifiers
31523358PMC6737425W2985543038What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.